US20060183746A1
(en)
*
|
2003-06-04 |
2006-08-17 |
Currie Kevin S |
Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds
|
TW200716551A
(en)
|
2005-03-10 |
2007-05-01 |
Cgi Pharmaceuticals Inc |
Certain substituted amides, method of making, and method of use thereof
|
US7893058B2
(en)
*
|
2006-05-15 |
2011-02-22 |
Janssen Pharmaceutica Nv |
Imidazolopyrazine compounds useful for the treatment of degenerative and inflammatory diseases
|
WO2007138072A2
(en)
|
2006-05-31 |
2007-12-06 |
Galapagos N.V. |
Triazolopyrazine compounds useful for the treatment of degenerative & inflammatory diseases
|
WO2008033858A2
(en)
*
|
2006-09-11 |
2008-03-20 |
Cgi Pharmaceuticals, Inc. |
Kinase inhibitors, and methods of using and identifying kinase inhibitors
|
PE20080839A1
(es)
*
|
2006-09-11 |
2008-08-23 |
Cgi Pharmaceuticals Inc |
Determinadas amidas sustituidas, metodo de elaboracion y metodo de uso de las mismas
|
HUE031334T2
(hu)
|
2006-09-22 |
2017-07-28 |
Pharmacyclics Llc |
Bruton-tirozinkináz inhibitorok
|
US8987233B2
(en)
|
2006-11-03 |
2015-03-24 |
Pharmacyclics, Inc. |
Bruton's tyrosine kinase activity probe and method of using
|
WO2008116064A2
(en)
|
2007-03-21 |
2008-09-25 |
Bristol-Myers Squibb Company |
Fused heterocyclic compounds useful for the treatment of proliferative, allergic, autoimmune or inflammatory diseases
|
US20120101114A1
(en)
|
2007-03-28 |
2012-04-26 |
Pharmacyclics, Inc. |
Inhibitors of bruton's tyrosine kinase
|
SG10202107066WA
(en)
*
|
2007-03-28 |
2021-07-29 |
Pharmacyclics Llc |
Inhibitors of bruton's tyrosine kinase
|
US8148369B2
(en)
|
2007-05-10 |
2012-04-03 |
Janssen Pharmaceutica Nv |
Fused pyrazine compounds useful for the treatment of degenerative and inflammatory diseases
|
EP2170892A2
(en)
*
|
2007-06-14 |
2010-04-07 |
Schering Corporation |
Imidazopyrazines as protein kinase inhibitors
|
WO2009012283A1
(en)
|
2007-07-17 |
2009-01-22 |
Plexxikon Inc. |
Compounds and methods for kinase modulation, and indications therefor
|
SG185330A1
(en)
|
2007-10-23 |
2012-11-29 |
Hoffmann La Roche |
Novel kinase inhibitors
|
US8426441B2
(en)
|
2007-12-14 |
2013-04-23 |
Roche Palo Alto Llc |
Inhibitors of bruton's tyrosine kinase
|
ES2462642T3
(es)
*
|
2007-12-14 |
2014-05-26 |
F. Hoffmann-La Roche Ag |
Nuevos derivados de imidazo[1,2-a]piridina e imidazo[1,2-b]piridazina
|
EP3311818A3
(en)
|
2008-07-16 |
2018-07-18 |
Pharmacyclics, LLC |
Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors
|
JP5341187B2
(ja)
|
2008-07-18 |
2013-11-13 |
エフ.ホフマン−ラ ロシュ アーゲー |
新規なフェニルイミダゾピラジン類
|
JP2011529073A
(ja)
|
2008-07-24 |
2011-12-01 |
ブリストル−マイヤーズ スクイブ カンパニー |
キナーゼ調節因子として有用な縮合ヘテロ環化合物
|
JP5696052B2
(ja)
|
2008-12-08 |
2015-04-08 |
ギリアード コネチカット, インコーポレイテッド |
イミダゾピラジンsyk阻害剤
|
KR20170013414A
(ko)
*
|
2008-12-08 |
2017-02-06 |
질레드 코네티컷 인코포레이티드 |
이미다조피라진 syk 억제제
|
WO2010068788A1
(en)
*
|
2008-12-10 |
2010-06-17 |
Cgi Pharmaceuticals, Inc. |
Heterocyclic amides as btk inhibitors
|
EP2391602B1
(en)
|
2008-12-19 |
2013-12-04 |
Bristol-Myers Squibb Company |
Carbazole carboxamide compounds useful as kinase inhibitors
|
US8765754B2
(en)
*
|
2009-04-29 |
2014-07-01 |
Locus Pharmaceuticals, Inc. |
Pyrrolotriazine compounds
|
CN102458402B
(zh)
|
2009-06-12 |
2013-10-02 |
百时美施贵宝公司 |
用作激酶调节剂的烟酰胺化合物
|
JP5641664B2
(ja)
|
2009-10-30 |
2014-12-17 |
ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプJanssen Pharmaceutica Naamloze Vennootschap |
イミダゾ[1,2−b]ピリダジン誘導体およびPDE10阻害剤としてのそれらの使用
|
AR080754A1
(es)
|
2010-03-09 |
2012-05-09 |
Janssen Pharmaceutica Nv |
Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10
|
KR101717809B1
(ko)
*
|
2010-03-11 |
2017-03-17 |
질레드 코네티컷 인코포레이티드 |
이미다조피리딘 syk 억제제
|
CN107898791A
(zh)
|
2010-06-03 |
2018-04-13 |
药品循环有限责任公司 |
布鲁顿酪氨酸激酶(btk)抑制剂的应用
|
EP2582668B1
(en)
|
2010-06-16 |
2016-01-13 |
Bristol-Myers Squibb Company |
Carboline carboxamide compounds useful as kinase inhibitors
|
EA027418B1
(ru)
|
2011-06-27 |
2017-07-31 |
Янссен Фармацевтика Нв |
ПРОИЗВОДНЫЕ 1-АРИЛ-4-МЕТИЛ[1,2,4]ТРИАЗОЛО[4,3-a]ХИНОКСАЛИНА, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ НА ИХ ОСНОВЕ, СПОСОБЫ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ ИХ, ПРОМЕЖУТОЧНЫЕ СОЕДИНЕНИЯ
|
KR20140048968A
(ko)
|
2011-07-13 |
2014-04-24 |
파마시클릭스, 인코포레이티드 |
브루톤형 티로신 키나제의 억제제
|
US8586387B2
(en)
*
|
2011-08-30 |
2013-11-19 |
Supernova Diagnostics, Inc. |
Methods of triggering activation of encapsulated signal-generating substances and apparatus utilising activated signal-generating substances
|
BR112014010391A2
(pt)
|
2011-11-03 |
2017-04-18 |
Hoffmann La Roche |
composto, composição farmacêutica, processo de produção de uma composição farmacêutica, método de tratamento, kit e uso de uma composição farmacêutica
|
KR101716011B1
(ko)
|
2011-11-03 |
2017-03-13 |
에프. 호프만-라 로슈 아게 |
Btk 활성의 억제제인 알킬화된 피페라진 화합물
|
UA111756C2
(uk)
|
2011-11-03 |
2016-06-10 |
Ф. Хоффманн-Ля Рош Аг |
Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона
|
AR088643A1
(es)
|
2011-11-03 |
2014-06-25 |
Genentech Inc |
Compuestos de 8-fluoroftalazin-1(2h)-ona
|
US8377946B1
(en)
|
2011-12-30 |
2013-02-19 |
Pharmacyclics, Inc. |
Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
|
MY194911A
(en)
|
2012-06-04 |
2022-12-22 |
Pharmacyclics Llc |
Crystalline forms of a bruton's tyrosine kinase inhibitor
|
ES2855575T3
(es)
|
2012-06-26 |
2021-09-23 |
Janssen Pharmaceutica Nv |
Combinaciones que comprenden compuestos de 4-metil-[1,2,4]triazolo[4,3-a]quinoxalina como inhibidores de PDE2 e inhibidores de PDE10 para su uso en el tratamiento de trastornos neurológicos o metabólicos
|
AU2013289284B2
(en)
|
2012-07-09 |
2017-03-30 |
Janssen Pharmaceutica Nv |
Inhibitors of phosphodiesterase 10 enzyme
|
MX2015001081A
(es)
|
2012-07-24 |
2015-10-14 |
Pharmacyclics Inc |
Mutaciones asociadas a resistencia a inhibidores de la tirosina cinasa de bruton (btk).
|
CN104854107A
(zh)
|
2012-11-15 |
2015-08-19 |
药品循环公司 |
作为激酶抑制剂的吡咯并嘧啶化合物
|
WO2014125410A1
(en)
*
|
2013-02-12 |
2014-08-21 |
Aurigene Discovery Technologies Limited |
N-substituted heterocyclic derivatives as kinase inhibitors
|
PL2989106T3
(pl)
|
2013-04-25 |
2017-08-31 |
Beigene, Ltd. |
Połączone związki heterocykliczne jako inhibitory kinazy białkowej
|
CN104119269A
(zh)
*
|
2013-04-25 |
2014-10-29 |
苏州科捷生物医药有限公司 |
一种6-异丙基烟酸的合成方法
|
WO2014210087A1
(en)
|
2013-06-25 |
2014-12-31 |
Bristol-Myers Squibb Company |
Carbazole carboxamide compounds useful as kinase inhibitors
|
AR096721A1
(es)
|
2013-06-25 |
2016-01-27 |
Bristol Myers Squibb Co |
Compuestos de tetrahidrocarbazol y carbazol carboxamida sustituidos
|
EP3016943B1
(en)
|
2013-07-03 |
2019-08-21 |
F. Hoffmann-La Roche AG |
Heteroaryl pyridone and aza-pyridone amide compounds
|
AP2016009007A0
(en)
|
2013-07-30 |
2016-01-31 |
Gilead Connecticut Inc |
Formulation of syk inhibitors
|
NZ715776A
(en)
|
2013-07-30 |
2017-04-28 |
Gilead Connecticut Inc |
Polymorph of syk inhibitors
|
WO2015017812A1
(en)
|
2013-08-02 |
2015-02-05 |
Pharmacyclics, Inc. |
Methods for the treatment of solid tumors
|
WO2015023703A1
(en)
|
2013-08-12 |
2015-02-19 |
Pharmacyclics, Inc. |
Methods for the treatment of her2 amplified cancer
|
KR102100419B1
(ko)
|
2013-09-13 |
2020-04-14 |
베이진 스위찰랜드 게엠베하 |
항-pd1 항체 및 이의 치료 및 진단 용도
|
TN2016000094A1
(en)
|
2013-09-30 |
2017-07-05 |
Pharmacyclics Llc |
Inhibitors of bruton's tyrosine kinase.
|
MX2016007311A
(es)
|
2013-12-04 |
2016-09-07 |
Gilead Sciences Inc |
Metodos para tratar canceres.
|
WO2015082583A1
(en)
|
2013-12-05 |
2015-06-11 |
F. Hoffmann-La Roche Ag |
Heteroaryl pyridone and aza-pyridone compounds with electrophilic functionality
|
TWI735853B
(zh)
|
2013-12-23 |
2021-08-11 |
美商克洛諾斯生技有限公司 |
脾酪胺酸激酶抑制劑
|
US9290505B2
(en)
|
2013-12-23 |
2016-03-22 |
Gilead Sciences, Inc. |
Substituted imidazo[1,2-a]pyrazines as Syk inhibitors
|
US9885086B2
(en)
|
2014-03-20 |
2018-02-06 |
Pharmacyclics Llc |
Phospholipase C gamma 2 and resistance associated mutations
|
CN106604742B
(zh)
|
2014-07-03 |
2019-01-11 |
百济神州有限公司 |
抗pd-l1抗体及其作为治疗剂及诊断剂的用途
|
KR20170029580A
(ko)
|
2014-07-14 |
2017-03-15 |
길리애드 사이언시즈, 인코포레이티드 |
암을 치료하기 위한 조합물
|
US9533991B2
(en)
|
2014-08-01 |
2017-01-03 |
Pharmacyclics Llc |
Inhibitors of Bruton's tyrosine kinase
|
JP2017523206A
(ja)
|
2014-08-07 |
2017-08-17 |
ファーマサイクリックス エルエルシー |
ブルトン型チロシンキナーゼ阻害剤の新規製剤
|
PL3209656T3
(pl)
|
2014-10-24 |
2020-12-14 |
Bristol-Myers Squibb Company |
Związki indolo-karboksyamidu użyteczne jako inhibitory kinazy
|
MX2017005060A
(es)
|
2014-10-24 |
2017-07-05 |
Bristol Myers Squibb Co |
Compuestos atropisomeros triciclicos.
|
AR102427A1
(es)
|
2014-10-24 |
2017-03-01 |
Bristol Myers Squibb Co |
Derivados de carbazol inhibidores de quinasas
|
EP3265084B1
(en)
|
2015-03-03 |
2023-11-22 |
Pharmacyclics LLC |
Pharmaceutical formulations of bruton's tyrosine kinase inhibtor
|
RU2017139771A
(ru)
*
|
2015-05-12 |
2019-06-13 |
Зено Роялтис Энд Майлстоунс, Ллс |
Бициклические соединения
|
US20170107216A1
(en)
|
2015-10-19 |
2017-04-20 |
Incyte Corporation |
Heterocyclic compounds as immunomodulators
|
RS63762B1
(sr)
|
2015-11-19 |
2022-12-30 |
Incyte Corp |
Heterociklična jedinjenja kao imunomodulatori
|
WO2017106634A1
(en)
*
|
2015-12-17 |
2017-06-22 |
Incyte Corporation |
N-phenyl-pyridine-2-carboxamide derivatives and their use as pd-1/pd-l1 protein/protein interaction modulators
|
KR20180100585A
(ko)
|
2015-12-22 |
2018-09-11 |
인사이트 코포레이션 |
면역조절제로서의 헤테로사이클릭 화합물
|
WO2017148837A1
(en)
|
2016-02-29 |
2017-09-08 |
F. Hoffmann-La Roche Ag |
Dosage form compositions comprising an inhibitor of bruton's tyrosine kinase
|
ES2906460T3
(es)
|
2016-05-06 |
2022-04-18 |
Incyte Corp |
Compuestos heterocíclicos como inmunomoduladores
|
TW201808902A
(zh)
|
2016-05-26 |
2018-03-16 |
美商英塞特公司 |
作為免疫調節劑之雜環化合物
|
AU2017281285C1
(en)
|
2016-06-20 |
2022-05-12 |
Incyte Corporation |
Heterocyclic compounds as immunomodulators
|
WO2018007885A1
(en)
|
2016-07-05 |
2018-01-11 |
Beigene, Ltd. |
COMBINATION OF A PD-l ANTAGONIST AND A RAF INHIBITOR FOR TREATING CANCER
|
WO2018013789A1
(en)
|
2016-07-14 |
2018-01-18 |
Incyte Corporation |
Heterocyclic compounds as immunomodulators
|
CN116478166A
(zh)
|
2016-08-16 |
2023-07-25 |
百济神州(苏州)生物科技有限公司 |
一种化合物的晶型、其制备和用途
|
AU2017313085A1
(en)
|
2016-08-19 |
2019-03-14 |
Beigene Switzerland Gmbh |
Use of a combination comprising a Btk inhibitor for treating cancers
|
US20180057486A1
(en)
*
|
2016-08-29 |
2018-03-01 |
Incyte Corporation |
Heterocyclic compounds as immunomodulators
|
WO2018049191A1
(en)
|
2016-09-09 |
2018-03-15 |
Incyte Corporation |
Pyrazolopyridone derivatives as hpk1 modulators and uses thereof for the treatment of cancer
|
US20180072718A1
(en)
|
2016-09-09 |
2018-03-15 |
Incyte Corporation |
Pyrazolopyridine compounds and uses thereof
|
TW201811799A
(zh)
|
2016-09-09 |
2018-04-01 |
美商英塞特公司 |
吡唑并嘧啶化合物及其用途
|
MX2019002750A
(es)
|
2016-09-09 |
2019-07-04 |
Incyte Corp |
Derivados de pirazolopiridina como moduladores de cinasa 1 progenitora hematopoyetica (hpk1) y usos de los mismos para tratamiento de cancer.
|
MX2019003134A
(es)
|
2016-09-19 |
2019-08-29 |
Mei Pharma Inc |
Terapia de combinacion.
|
PT3558990T
(pt)
|
2016-12-22 |
2022-11-21 |
Incyte Corp |
Derivados de tetrahidroimidazo[4,5-c]piridina como indutores da internalização de pd-l1
|
PE20191532A1
(es)
|
2016-12-22 |
2019-10-23 |
Incyte Corp |
Compuestos heterociclicos como inmunomoduladores
|
EP3558989B1
(en)
|
2016-12-22 |
2021-04-14 |
Incyte Corporation |
Triazolo[1,5-a]pyridine derivatives as immunomodulators
|
MA47120A
(fr)
|
2016-12-22 |
2021-04-28 |
Incyte Corp |
Dérivés pyridine utilisés en tant qu'immunomodulateurs
|
EP3573989A4
(en)
|
2017-01-25 |
2020-11-18 |
Beigene, Ltd. |
CRYSTALLINE FORMS OF (S) -7- (1- (BUT-2-YNOYL) -PIPERIDINE-4-YL) -2- (4-PHENOXYPHENYL) -4,5,6,7-TETRAHYDROPYRAZOLO [1,5-A ] PYRIMIDINE-3-CARBOXAMIDE, MANUFACTURING AND USES THEREOF
|
US20180228786A1
(en)
|
2017-02-15 |
2018-08-16 |
Incyte Corporation |
Pyrazolopyridine compounds and uses thereof
|
CN110709702A
(zh)
|
2017-03-24 |
2020-01-17 |
豪夫迈·罗氏有限公司 |
治疗自身免疫性疾病和炎性疾病的方法
|
EP3645569A4
(en)
|
2017-06-26 |
2021-03-24 |
BeiGene, Ltd. |
IMMUNOTHERAPY FOR LIVER CELL CARCINOMA
|
WO2019034009A1
(en)
|
2017-08-12 |
2019-02-21 |
Beigene, Ltd. |
BTK INHIBITOR WITH ENHANCED DOUBLE SELECTIVITY
|
JP6986624B2
(ja)
|
2017-08-25 |
2021-12-22 |
ギリアード サイエンシーズ, インコーポレイテッド |
Syk阻害剤の多形体
|
US10722495B2
(en)
|
2017-09-08 |
2020-07-28 |
Incyte Corporation |
Cyanoindazole compounds and uses thereof
|
US11786529B2
(en)
|
2017-11-29 |
2023-10-17 |
Beigene Switzerland Gmbh |
Treatment of indolent or aggressive B-cell lymphomas using a combination comprising BTK inhibitors
|
MD3755703T2
(ro)
|
2018-02-20 |
2022-10-31 |
Incyte Corp |
Derivați N-(fenil)-2-(fenil)pirimidin-4-carboxamidă și compuși înrudiți ca inhibitori HPK1 pentru tratarea cancerului
|
US10752635B2
(en)
|
2018-02-20 |
2020-08-25 |
Incyte Corporation |
Indazole compounds and uses thereof
|
US10745388B2
(en)
|
2018-02-20 |
2020-08-18 |
Incyte Corporation |
Indazole compounds and uses thereof
|
DK3774791T3
(da)
|
2018-03-30 |
2023-01-23 |
Incyte Corp |
Heterocykliske forbindelser som immunmodulatorer
|
US11299473B2
(en)
|
2018-04-13 |
2022-04-12 |
Incyte Corporation |
Benzimidazole and indole compounds and uses thereof
|
BR112020022936A2
(pt)
|
2018-05-11 |
2021-02-02 |
Incyte Corporation |
derivados de tetra-hidro-imidazo[4,5-c]piridina como imunomoduladores de pd-l1
|
US10899755B2
(en)
|
2018-08-08 |
2021-01-26 |
Incyte Corporation |
Benzothiazole compounds and uses thereof
|
JP7399968B2
(ja)
|
2018-09-25 |
2023-12-18 |
インサイト・コーポレイション |
Alk2及び/またはfgfr調節剤としてのピラゾロ[4,3-d]ピリミジン化合物
|
AU2020225455A1
(en)
|
2019-02-22 |
2021-09-09 |
Kronos Bio, Inc. |
Solid forms of condensed pyrazines as Syk inhibitors
|
BR112022002059A2
(pt)
|
2019-08-06 |
2022-06-07 |
Incyte Corp |
Formas sólidas de um inibidor de hpk1
|
WO2021030162A1
(en)
|
2019-08-09 |
2021-02-18 |
Incyte Corporation |
Salts of a pd-1/pd-l1 inhibitor
|
CR20220190A
(es)
|
2019-09-30 |
2022-06-15 |
Incyte Corp |
Compuestos de pirido [3,2-d] primidina como inmunomoduladores
|
WO2021096849A1
(en)
|
2019-11-11 |
2021-05-20 |
Incyte Corporation |
Salts and crystalline forms of a pd-1/pd-l1 inhibitor
|
US11780836B2
(en)
|
2020-11-06 |
2023-10-10 |
Incyte Corporation |
Process of preparing a PD-1/PD-L1 inhibitor
|
WO2022099075A1
(en)
|
2020-11-06 |
2022-05-12 |
Incyte Corporation |
Crystalline form of a pd-1/pd-l1 inhibitor
|
IL302590A
(en)
|
2020-11-06 |
2023-07-01 |
Incyte Corp |
Process for preparing PD-1/PD-L1 inhibitor and salts and crystalline forms thereof
|
US11786531B1
(en)
|
2022-06-08 |
2023-10-17 |
Beigene Switzerland Gmbh |
Methods of treating B-cell proliferative disorder
|